Awaiting development: Guidance and quality standards

Skip to filters Skip to results

Showing 151 to 160 of 381

Type: Guidance`Remove $Type: Guidance filter`

Guidance and quality standards awaiting development
Title	Type
Imlunestrant for adjuvant treatment of ER-positive, HER2-negative early breast cancer with increased risk of recurrence	Technology appraisal guidance
Inavolisib with fulvestrant for treating recurrent hormone receptor-positive HER2-negative PIK3CA-mutated locally advanced or metastatic breast cancer after a CDK 4-6 inhibitor [ID6650]	Technology appraisal guidance
Inavolisib with pertuzumab–trastuzumab for maintenance treatment of PIK3CA-mutated HER2-positive advanced breast cancer after induction chemotherapy	Technology appraisal guidance
Inclisiran for treating familial hypercholesterolaemia and elevated low density lipoprotein cholesterol in people 12 to 17 years [TSID12129]	Technology appraisal guidance
Inebilizumab for treating AQP4-IgG-seropositive neuromyelitis optica spectrum disorders [ID6430]	Technology appraisal guidance
Inebilizumab for treating generalised myasthenia gravis [ID6587] [TSID12110]	Technology appraisal guidance
Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]	Technology appraisal guidance
Invimestrocel for treating acute ischaemic stroke within 18 to 36 hours of onset [TSID10190]	Technology appraisal guidance
Iodine (131I)–apamistamab for treating relapsed or refractory acute myeloid leukaemia before an allogeneic haematopoietic stem cell transplant [ID6355]	Technology appraisal guidance
Irbesartan–propagermanium for treating focal segmental glomerulosclerosis in people 12 years and over having an angiotensin II receptor blocker [ID6469]	Technology appraisal guidance

Results per page

10
25
50
All